145 related articles for article (PubMed ID: 26949913)
1. A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Kloor M; Prigge ES; Sauer M; Al-Batran SE; Kaufmann AM; Schneider A; Jäger E; von Knebel Doeberitz M
Cancer; 2016 May; 122(9):1425-33. PubMed ID: 26949913
[TBL] [Abstract][Full Text] [Related]
2. [Targeting p16(INK4a) by therapeutic vaccination : Concept and status of clinical investigations in HPV-associated head and neck cancers].
Reuschenbach M
HNO; 2015 Feb; 63(2):104-10. PubMed ID: 25515124
[TBL] [Abstract][Full Text] [Related]
3. No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.
Prigge ES; Urban K; Stiegler S; Müller M; Kloor M; Mai S; Ottstadt M; Lohr F; Wenz F; Wagner S; Wittekindt C; Klussmann JP; Hampl M; von Knebel Doeberitz M; Reuschenbach M
Hum Pathol; 2014 Nov; 45(11):2347-54. PubMed ID: 25257576
[TBL] [Abstract][Full Text] [Related]
4. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
5. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers.
Reuschenbach M; Waterboer T; Wallin KL; Einenkel J; Dillner J; Hamsikova E; Eschenbach D; Zimmer H; Heilig B; Kopitz J; Pawlita M; Doeberitz Mv; Wentzensen N
Int J Cancer; 2008 Dec; 123(11):2626-31. PubMed ID: 18785210
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of expression and lack of 5' CpG island hypermethylation of p16 INK4a in HPV-positive cervical carcinomas.
Ivanova TA; Golovina DA; Zavalishina LE; Volgareva GM; Katargin AN; Andreeva YY; Frank GA; Kisseljov FL; Kisseljova NP
BMC Cancer; 2007 Mar; 7():47. PubMed ID: 17359536
[TBL] [Abstract][Full Text] [Related]
7. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer.
Hoffmann M; Ihloff AS; Görögh T; Weise JB; Fazel A; Krams M; Rittgen W; Schwarz E; Kahn T
Int J Cancer; 2010 Oct; 127(7):1595-602. PubMed ID: 20091864
[TBL] [Abstract][Full Text] [Related]
8. Combination of p16(INK4a) /Ki67 immunocytology and HPV polymerase chain reaction for the noninvasive analysis of HPV involvement in head and neck cancer.
Linxweiler M; Bochen F; Wemmert S; Lerner C; Hasenfus A; Bohle RM; Al-Kadah B; Takacs ZF; Smola S; Schick B
Cancer Cytopathol; 2015 Apr; 123(4):219-29. PubMed ID: 25557267
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
[TBL] [Abstract][Full Text] [Related]
10. Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer.
Kanao H; Enomoto T; Ueda Y; Fujita M; Nakashima R; Ueno Y; Miyatake T; Yoshizaki T; Buzard GS; Kimura T; Yoshino K; Murata Y
Cancer Lett; 2004 Sep; 213(1):31-7. PubMed ID: 15312681
[TBL] [Abstract][Full Text] [Related]
11. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.
Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J
J Clin Oncol; 2009 Apr; 27(12):1992-8. PubMed ID: 19289615
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.
Garcia-Bates TM; Kim E; Concha-Benavente F; Trivedi S; Mailliard RB; Gambotto A; Ferris RL
J Immunol; 2016 Mar; 196(6):2870-8. PubMed ID: 26851223
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus infection in Bowen disease: negative p53 expression, not p16(INK4a) overexpression, is correlated with human papillomavirus-associated Bowen disease.
Murao K; Yoshioka R; Kubo Y
J Dermatol; 2014 Oct; 41(10):878-84. PubMed ID: 25201325
[TBL] [Abstract][Full Text] [Related]
14. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
15. Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology.
Allia E; Ronco G; Coccia A; Luparia P; Macrì L; Fiorito C; Maletta F; Deambrogio C; Tunesi S; De Marco L; Gillio-Tos A; Sapino A; Ghiringhello B
Cancer Cytopathol; 2015 Apr; 123(4):212-8. PubMed ID: 25534957
[TBL] [Abstract][Full Text] [Related]
16. Validation of Human Papillomavirus as a Favourable Prognostic Marker and Analysis of CD8
Sivars L; Landin D; Grün N; Vlastos A; Marklund L; Nordemar S; Ramqvist T; Munck-Wikland E; Näsman A; Dalianis T
Anticancer Res; 2017 Feb; 37(2):665-673. PubMed ID: 28179315
[TBL] [Abstract][Full Text] [Related]
17. P16INK4a expression, human papillomavirus, and survival in head and neck cancer.
Smith EM; Wang D; Kim Y; Rubenstein LM; Lee JH; Haugen TH; Turek LP
Oral Oncol; 2008 Feb; 44(2):133-42. PubMed ID: 17360226
[TBL] [Abstract][Full Text] [Related]
18. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
[TBL] [Abstract][Full Text] [Related]
19. Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus.
Ferreux E; Lont AP; Horenblas S; Gallee MP; Raaphorst FM; von Knebel Doeberitz M; Meijer CJ; Snijders PJ
J Pathol; 2003 Sep; 201(1):109-18. PubMed ID: 12950023
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Wada H; Isobe M; Kakimi K; Mizote Y; Eikawa S; Sato E; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Yamasaki M; Miyata H; Matsushita H; Udono H; Seto Y; Yamada K; Nishikawa H; Pan L; Venhaus R; Oka M; Doki Y; Nakayama E
J Immunother; 2014; 37(2):84-92. PubMed ID: 24509171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
